Hanmi Pharm. Co., Ltd. (KRX:128940)
South Korea flag South Korea · Delayed Price · Currency is KRW
426,000
+18,500 (4.54%)
Last updated: Aug 11, 2026, 9:58 AM KST

Hanmi Pharm. Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1,549,5091,547,5311,495,5021,490,8871,331,5471,203,186
Revenue Growth
4.50%3.48%0.31%11.97%10.67%11.83%
Gross Profit
888,104884,407817,037829,249718,553632,752
Operating Income
210,588223,870212,511224,885153,896125,416
Net Income
172,439169,554121,315146,23182,79267,025
Earnings Per Share
13587.9413362.009566.8311522.126517.335269.87
EPS Growth
58.19%39.67%-16.97%76.79%23.67%461.07%

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Medicine
1,136,7721,146,6221,114,1231,096,946982,049917,018
Active Pharmaceutical Ingredients
90,16791,280108,892111,067100,54787,158
Overseas Pharmaceuticals
412,309402,395385,630397,690350,640288,729
Reconciliation of Inter-Sector Transactions
-89,739-92,766-113,143-114,815-101,689-89,719
Total
1,549,5091,547,5311,495,5021,490,8871,331,5471,203,186

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
298,382201,322193,195255,183236,736211,734
Total Debt
418,363434,211496,687572,867678,323756,267
Net Cash (Debt)
-119,981-232,889-303,492-317,685-441,586-544,532
Net Cash Growth
------
Net Cash Per Share
-9454.25-18353.48-23933.19-25031.60-34761.50-42813.87

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
205,368173,072193,487216,538162,269201,923
Capital Expenditures
-51,451-43,025-39,261-27,352-30,378-19,949
Free Cash Flow
153,918130,048154,226189,186131,890181,974
Free Cash Flow Growth
38.45%-15.68%-18.48%43.44%-27.52%65.85%

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
57.32%57.15%54.63%55.62%53.96%52.59%
Operating Margin
13.59%14.47%14.21%15.08%11.56%10.42%
Pretax Margin
13.92%13.79%11.45%13.01%9.09%8.62%
Profit Margin
11.13%10.96%8.11%9.81%6.22%5.57%
FCF Margin
9.93%8.40%10.31%12.69%9.90%15.12%

Dividends

Fiscal YearCurrentFY 2025
Period EndingAug '26 Dec '25
Dividend Per Share
2000.0002000.000
Dividend Per Share Growth
0%-
Dividend Yield
0.51%0.44%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
29.9933.8029.3230.5944.8350.34
Forward PE
24.5533.6419.5430.5738.0144.63
P/FCF Ratio
33.5944.0723.0623.6528.1418.54
PS Ratio
3.343.702.383.002.792.80